Breast Cancer
RlapsRisk BC

Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides

View publication
July 1, 2025
|
Nature Communications

Abstract

Accurate risk stratification is critical for guiding treatment decisions in early breast cancer. We present an artificial intelligence (AI)-based tool that analyzes digitized tumor slides to predict 5-year metastasis-free survival (MFS) in patients with estrogen receptor-positive, HER2-negative (ER + /HER2 − ) early breast cancer (EBC).

Our deep learning model, RlapsRisk BC, independently predicts MFS and provides significant prognostic value beyond traditional clinico-pathological variables (C-index 0.81 vs 0.76, p < 0.05). Applying a 5% MFS event probability threshold stratifies patients into low- and high-risk groups. After dichotomization, combining RlapsRisk BC with clinico-pathological factors increases cumulative sensitivity (0.69 vs 0.63) and dynamic specificity (0.80 vs 0.76) compared to clinical factors alone. Expert analysis of high-impact regions identified by the model highlights well- established morphological features, supporting its interpretability and biological relevance.

View publication
Arrow

Authors

Ingrid Garberis, Valentin Gaury, Charlie Saillard, Damien Drubay, Kevin Elgui, Benoit Schmauch, Alexandre Jaeger, Loic Herpin, Julia Linhart, M. Sapateiro, F. Bernigole, Alexandre Filiot, Oussama Tchita, Remy Dubois, Michaël Auffret, Lionel Guillou, Imad Bousaid, Mikael Azoulay, Jerome Lemonnier, Meriem Sefta, PhD, S. Everhard, A. Sarrazin, Jean-François Reboud, Fabien Brulport, Jocelyn Dachary, Barbara Pistilli, Suzette Delaloge, Pierre Courtiol, Prof. Fabrice André, MD, PhD, Victor Aubert, Magali Lacroix-Triki, M.D., PhD